"Breast Neoplasms, Male" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
| Descriptor ID |
D018567
|
| MeSH Number(s) |
C04.588.180.260 C17.800.090.500.260
|
| Concept/Terms |
Breast Neoplasms, Male- Breast Neoplasms, Male
- Breast Neoplasm, Male
- Male Breast Neoplasm
- Neoplasm, Male Breast
- Tumors, Breast, Male
- Neoplasms, Breast, Male
- Neoplasms, Male Breast
- Breast Tumors, Male
- Breast Tumor, Male
- Male Breast Tumor
- Male Breast Tumors
- Tumor, Male Breast
- Tumors, Male Breast
- Male Breast Neoplasms
Male Breast Cancer- Male Breast Cancer
- Cancer, Male Breast
- Breast Carcinoma, Male
- Carcinoma, Male Breast
- Male Breast Carcinoma
- Breast Cancer, Male
|
Below are MeSH descriptors whose meaning is more general than "Breast Neoplasms, Male".
Below are MeSH descriptors whose meaning is more specific than "Breast Neoplasms, Male".
This graph shows the total number of publications written about "Breast Neoplasms, Male" by people in this website by year, and whether "Breast Neoplasms, Male" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Breast Neoplasms, Male" by people in Profiles.
-
Rates of newly diagnosed breast cancer at commission on cancer facilities during the early phase of the COVID-19 pandemic. Cancer Med. 2024 Jan; 13(1):e6874.
-
Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study. Ann Surg Oncol. 2022 Oct; 29(10):6115-6131.
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
-
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
-
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019 Jul; 25(5):1112-1118.
-
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
-
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
-
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016 06 01; 22(11):2659-67.
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15.
-
Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer. Cancer. 2014 Apr 01; 120(7):963-7.